185 related articles for article (PubMed ID: 12720492)
1. The role of 5-HT on the cardiovascular and renal systems and the clinical potential of 5-HT modulation.
Doggrell SA
Expert Opin Investig Drugs; 2003 May; 12(5):805-23. PubMed ID: 12720492
[TBL] [Abstract][Full Text] [Related]
2. 5-hydroxytryptamine and cardiovascular regulation.
Ramage AG; Villalón CM
Trends Pharmacol Sci; 2008 Sep; 29(9):472-81. PubMed ID: 19086344
[TBL] [Abstract][Full Text] [Related]
3. In vitro activity of LY393558, an inhibitor of the 5-hydroxytryptamine transporter with 5-HT(1B/1D/2) receptor antagonist properties.
Pullar IA; Boot JR; Carney SL; Cohen ML; Colvin EM; Conway RG; Hardy CH; Lucaites VL; Nelson DL; Schenck KW; Tomlinson R; Wedley S
Eur J Pharmacol; 2001 Nov; 432(1):9-17. PubMed ID: 11734182
[TBL] [Abstract][Full Text] [Related]
4. Cardiovascular responses produced by 5-hydroxytriptamine:a pharmacological update on the receptors/mechanisms involved and therapeutic implications.
Villalón CM; Centurión D
Naunyn Schmiedebergs Arch Pharmacol; 2007 Oct; 376(1-2):45-63. PubMed ID: 17703282
[TBL] [Abstract][Full Text] [Related]
5. LY367265, an inhibitor of the 5-hydroxytryptamine transporter and 5-hydroxytryptamine(2A) receptor antagonist: a comparison with the antidepressant, nefazodone.
Pullar IA; Carney SL; Colvin EM; Lucaites VL; Nelson DL; Wedley S
Eur J Pharmacol; 2000 Oct; 407(1-2):39-46. PubMed ID: 11050288
[TBL] [Abstract][Full Text] [Related]
6. Multiple 5-HT receptors in passive avoidance: comparative studies of p-chloroamphetamine and 8-OH-DPAT.
Misane I; Ogren SO
Neuropsychopharmacology; 2000 Feb; 22(2):168-90. PubMed ID: 10649830
[TBL] [Abstract][Full Text] [Related]
7. Serotonin-induced smooth muscle hyperplasia in various forms of human pulmonary hypertension.
Marcos E; Fadel E; Sanchez O; Humbert M; Dartevelle P; Simonneau G; Hamon M; Adnot S; Eddahibi S
Circ Res; 2004 May; 94(9):1263-70. PubMed ID: 15059929
[TBL] [Abstract][Full Text] [Related]
8. Proliferation and signaling in fibroblasts: role of 5-hydroxytryptamine2A receptor and transporter.
Welsh DJ; Harnett M; MacLean M; Peacock AJ
Am J Respir Crit Care Med; 2004 Aug; 170(3):252-9. PubMed ID: 15087293
[TBL] [Abstract][Full Text] [Related]
9. Serotonin transporter inhibitors protect against hypoxic pulmonary hypertension.
Marcos E; Adnot S; Pham MH; Nosjean A; Raffestin B; Hamon M; Eddahibi S
Am J Respir Crit Care Med; 2003 Aug; 168(4):487-93. PubMed ID: 12773327
[TBL] [Abstract][Full Text] [Related]
10. Peripheral 5-HT₁D and 5-HT₇ serotonergic receptors modulate sympathetic neurotransmission in chronic sarpogrelate treated rats.
García-Pedraza JÁ; García M; Martín ML; Gómez-Escudero J; Rodríguez-Barbero A; Román LS; Morán A
Eur J Pharmacol; 2013 Aug; 714(1-3):65-73. PubMed ID: 23769743
[TBL] [Abstract][Full Text] [Related]
11. 5-Hydroxytryptamine (serotonin): biphasic dose responses.
Calabrese EJ
Crit Rev Toxicol; 2001 Jul; 31(4-5):553-61. PubMed ID: 11504181
[TBL] [Abstract][Full Text] [Related]
12. Blockade of 5-HT(2A) receptors by sarpogrelate protects the heart against myocardial infarction in rats.
Brasil D; Temsah RM; Kumar K; Kumamoto H; Takeda N; Dhalla NS
J Cardiovasc Pharmacol Ther; 2002 Jan; 7(1):53-9. PubMed ID: 12000979
[TBL] [Abstract][Full Text] [Related]
13. Role of serotonin in gastrointestinal physiology and pathology.
Cirillo C; Vanden Berghe P; Tack J
Minerva Endocrinol; 2011 Dec; 36(4):311-24. PubMed ID: 22322654
[TBL] [Abstract][Full Text] [Related]
14. Chronic 5-HT
García-Pedraza JÁ; Hernández-Abreu O; García M; Morán A; Villalón CM
Can J Physiol Pharmacol; 2018 Apr; 96(4):328-336. PubMed ID: 28886249
[TBL] [Abstract][Full Text] [Related]
15. The role of serotonin in ischemic cellular damage and the infarct size-reducing effect of sarpogrelate, a 5-hydroxytryptamine-2 receptor blocker, in rabbit hearts.
Shimizu Y; Minatoguchi S; Hashimoto K; Uno Y; Arai M; Wang N; Chen X; Lu C; Takemura G; Shimomura M; Fujiwara T; Fujiwara H
J Am Coll Cardiol; 2002 Oct; 40(7):1347-55. PubMed ID: 12383585
[TBL] [Abstract][Full Text] [Related]
16. The serotonin receptor and transporter as potential therapeutic targets for pulmonary hypertension.
Wang HL
Curr Opin Investig Drugs; 2004 Sep; 5(9):963-6. PubMed ID: 15503652
[TBL] [Abstract][Full Text] [Related]
17. Activated platelets contribute to stimulation of cardiac afferents during ischaemia in cats: role of 5-HT(3) receptors.
Fu LW; Longhurst JC
J Physiol; 2002 Nov; 544(3):897-912. PubMed ID: 12411532
[TBL] [Abstract][Full Text] [Related]
18. Inverse agonist activity of sarpogrelate, a selective 5-HT2A-receptor antagonist, at the constitutively active human 5-HT2A receptor.
Muntasir HA; Bhuiyan MA; Ishiguro M; Ozaki M; Nagatomo T
J Pharmacol Sci; 2006 Oct; 102(2):189-95. PubMed ID: 17031071
[TBL] [Abstract][Full Text] [Related]
19. Serotonin receptors and therapeutics.
Launay JM; Callebert J; Bondoux D; Loric S; Maroteaux L
Cell Mol Biol (Noisy-le-grand); 1994 May; 40(3):327-36. PubMed ID: 7522716
[TBL] [Abstract][Full Text] [Related]
20. Evidence for 5-HT(1B/1D) and 5-HT(2A) receptors mediating constriction of the canine internal carotid circulation.
Centurión D; Ortiz MI; Sánchez-López A; De Vries P; Saxena PR; Villalón CM
Br J Pharmacol; 2001 Mar; 132(5):983-90. PubMed ID: 11226128
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
